Last updated: February 22, 2026
What is the Drug Associated with NDC 70000-0011?
NDC 70000-0011 corresponds to Remdesivir (Veklury), developed by Gilead Sciences. Approved by the FDA in late 2020 for COVID-19 treatment, it has since been authorized for use in certain hospitalized patients. The drug is administered intravenously and is classified as an antiviral nucleotide analog.
Market Size and Trends
Demographic and Epidemiological Factors
- Global COVID-19 cases (as of early 2023): Exceeding 750 million infections, with hospitalization rates around 10%.
- Target patient population: Hospitalized COVID-19 patients eligible for antiviral therapy.
- Market penetration: Initial uptake in high-income countries, expansion to lower-income markets with increased supply and pricing negotiations.
Key Market Drivers
- Regulatory approvals: Expanded to include multiple countries and emergency use authorizations.
- Clinical efficacy: Proven reduction in recovery time and severity in hospitalized patients.
- Treatment protocols: Inclusion in standard-of-care guidelines for COVID-19.
Competitive Landscape
- Alternatives: Paxlovid (Pfizer), Molnupiravir (Merck), Evusheld (AstraZeneca) for prophylaxis.
- Market share: Remdesivir held approximately 60%-70% of COVID-19 antiviral admissions in 2022 in developed nations.
Market Challenges
- Emergence of new variants: Some evidence suggests variable efficacy.
- Pricing and reimbursement policies: Vary significantly across countries.
- Supply constraints: Limited manufacturing capacity initially, now expanding.
Current Pricing Structure
Approved Pricing
- U.S. (2022): Approximate wholesale acquisition cost (WAC): $520 per 100 mg vial.
- Treatment course: Typically 6 vials, totaling roughly $3,120.
- Reimbursement: Medicare/Medicaid prices aligned with WAC plus negotiated discounts.
International Pricing
- Canada: Approximately $2,950 USD per treatment course.
- European Union: Approximately €2,500-€3,000, depending on negotiated discounts.
Reimbursement Policies
- U.S.: Fully reimbursed through Medicare, Medicaid, and private insurers.
- Europe: Reimbursement varies with national health systems.
Price Projections (2023-2028)
| Year |
Estimated Global Sales (USD billion) |
Price per Course (USD) |
Market Penetration |
Key Assumptions |
| 2023 |
4.0 |
$3,200 |
60% in hospital settings |
Continued viral evolution, stable demand, expanding global access |
| 2024 |
5.0 |
$3,300 |
70% in hospital settings |
Widespread use in emerging markets, negotiated price reductions |
| 2025 |
6.0 |
$3,400 |
75% in hospital settings |
New variants emerging, potential new indications |
| 2026 |
7.0 |
$3,500 |
80% in hospital settings |
Market stabilization, generic competition emergence |
| 2027 |
8.0 |
$3,600 |
85% in hospital settings |
Increased use for prophylactic applications |
| 2028 |
8.5 |
$3,650 |
85% in hospital settings |
Market saturation, stable pricing |
Key Factors Affecting Price Dynamics
- Patent status: Gilead’s patents are set to expire around 2027, opening potential for generic competition.
- Manufacturing expansion: Will reduce costs as capacity increases.
- Regulatory and policy changes: May influence reimbursement and access, especially in low-income countries.
- Clinical data: Additional data supporting broader or narrower use can shift demand and price.
Competitive Outlook
- Post-patent expiration, generic versions could reduce prices by 50% or more.
- Price stabilization expected in mid-to-late 2020s, contingent on market penetration and competition.
- New antiviral agents in development may further impact pricing strategies.
Key Takeaways
- NDC 70000-0011 (Remdesivir) remains a significant antiviral in the COVID-19 treatment space.
- Sales are driven by hospitalizations, with prices averaging around $3,200 per course in the U.S.
- Market growth depends on viral evolution, regulatory access, and competitive pressures.
- Price projections suggest gradual increases in global sales, with potential for substantial reductions after patent expiration.
- Manufacturers and investors should monitor patent timelines, manufacturing scalability, and emerging competition.
FAQs
1. How does the patent status influence future pricing for Remdesivir?
Patent expiration around 2027 may lead to generic versions entering the market, significantly reducing prices.
2. What are the main competitors to Remdesivir?
Paxlovid (Pfizer), Molnupiravir (Merck), and prophylactic agents like Evusheld.
3. How do reimbursement policies vary internationally?
U.S. prices are largely reimbursement-friendly; European countries have variable reimbursements based on national health policies.
4. Will new COVID-19 variants affect Remdesivir demand?
Yes; if variants reduce efficacy or alter treatment protocols, demand could decline or shift.
5. What factors could accelerate price reductions?
Patent expiration, increased manufacturing capacity, and entrance of lower-cost generics.
References
[1] Gilead Sciences. (2022). Veklury (Remdesivir) product information. Retrieved from https://www.gilead.com
[2] IQVIA. (2023). Global Market Reports on COVID-19 antivirals.
[3] U.S. Food & Drug Administration. (2020). Remdesivir Emergency Use Authorization. Retrieved from https://www.fda.gov
[4] European Medicines Agency. (2022). Remdesivir approval details. Retrieved from https://www.ema.europa.eu
[5] World Health Organization. (2022). COVID-19 clinical management guidelines. Retrieved from https://www.who.int
